In vitro effect of calcium dobesilate on oxidative/inflammatory stress in human varicose veins

Phlebology

Volumn 26, Issue 8, 2011, Pages 332-337

  Alda, O ^a   Valero, M S ^a   Pereboom, D ^a   Serrano, P ^b   Azcona, J M ^c   Garay, R P ^d  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d Universite Paris Sud   (France)

Author keywords

Calcium dobesilate; Free radicals; Human; Varicose veins; Veins

Indexed keywords

DOBESILATE CALCIUM; MALONALDEHYDE; PHENAZINE METHOSULFATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RUTOSIDE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC VEIN INSUFFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG MECHANISM; FEMALE; HUMAN; IC 50; IN VITRO STUDY; INFLAMMATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SAPHENOUS VEIN;

AGED; ANTIOXIDANTS; CALCIUM DOBESILATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOSTATICS; HUMANS; INFLAMMATION; MALE; MALONDIALDEHYDE; METHYLPHENAZONIUM METHOSULFATE; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; SAPHENOUS VEIN; VARICOSE VEINS;

EID: 83255162685     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2010.010052     Document Type: Article

References (29)

1. Ciapponi A, Laffaire E, Roque M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004;55:147-54
2. Espinosa JD, Giannone CA. Tratamiento de la insuficiencia venosa crónica con dobesilato de calcio. Un meta-análisis. Flebología 2001;1:15-20
3. Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews. 2005;3:Art. No.: CD003229
4. Ramelet AA, Boisseau MR, Allegra C, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: Current medical position, prospective views and final resolution. Clin Hemorheol Microcircul 2005;33:309-19
5. Flota-Cervera F, Flota-Ruiz C, Trevino C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008;59:352-6
6. Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998;12:205-12
7. Szabo ME, Haines D, Garay E, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001;428:277-86
8. Lozovskaia EL, Kaplunskii ̌ GD, Sapezhinskii ̌ II. Superoxide dismutase activity and photosensitizing properties of 2,5-dihydroxybenzolsulfonate. Biofizika 1990;35: 912-6
9. Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacology 1997;121:711-6
10. Brunet J, Farine J-C, Garay RP, Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. European Journal of Pharmacol 1998;358:213-20
11. Bozkurt AK, Konukoǧlu D, Ustündaǧ N, Yüceyar L, Mayda AS. Calcium dobesilate ameliorates lung injury following lower limb ischemia/reperfusion. Drugs Exp Clin Res 2002;28:127-32
12. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005;4:221-32
13. Rota R, Chiavaroli C, Garay RP, Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004;495:217-24
14. Lameynardie S, Chiavaroli C, Travo P, Garay RP, ParÈ s-HerbutÈ Nr. Inhibition of choroidal angiogenesisby calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol 2005;510:149-56
15. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology 2005;56(6_suppl):S11-9
16. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta (BBA) - Mol Cell Res 2000;1497:1-10
17. Jacob M-P, Cazaubon M, Scemama A, et al. Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 2002;106:535-8
18. Glowinski J, Glowinski S. Generation of reactive oxygen metabolites by the varicose vein wall. Eur J Vas Endovasc Surg 2002;23:550-5
19. Flore R, Santoliquido A, Antonio DL, et al. Long saphenous vein stripping reduces local level of reactive oxygen metabolites in patients with varicose disease of the lower limbs. World J Surg 2003;27:473-5
20. Smith PD. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 1999;36(Suppl 1):24-36
21. Han D-W, Suh H, Park YH, Cho BK, Hyon S-H, Park J-C. Preservation of human saphenous vein against reactive oxygen species-induced oxidative stress by Green Tea Polyphenol Pretreatment. Artif Organs 2003;27:1137-42
22. Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: Consensus statement. J Vasc Surg 2004;40:1248-52
23. Benakis A, Glasson B, Bouvier CA. Metabolism and pharmacokinetics of calcium dobesilate in humans. Therapie 1974;29:211-9
24. Bradbury AW, Murie JA, Ruckley CV. Role of the leucocyte in the pathogenesis of vascular disease. Br J Surg 1993;80:1503-12
25. Phan SH, Gannon DE, Ward PA, Karmiol S. Mechanism of neutrophil-induced xanthine dehydrogenase to xanthine oxidase conversion in endothelial cells: evidence of a role for elastase. Am J Respir Cell Mol Biol 1992;6:270-8
26. Karatepe O, Unal O, Ugurlucan M, et al. The impact of valvular oxidative stress on the development of venous stasis ulcer valvular oxidative stress and venous ulcers. Angiology 2009;61:283-8
27. Zamboni P, Lanzara S, Mascoli F, Caggiati A, Liboni A. Inflammation in venous disease. Int Angiol 2008;27: 361-9
28. Auteri A, Pasqui AL, Bruni F, et al. Pharmacodynamics and pharmacokinetics of Veliten (rutine, alpha-tocopherol and ascorbic acid) in patients with chronic venous insufficiency. Int J Clin Pharmacol Res 1994;14:95-100
29. Aguilar Peralta GR, Arévalo Gardoqui J, Llamas Macías FJ, Navarro Ceja VH, Mendoza Cisneros SA, Martínez Macías CG. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. Int Angiol 2007;26:378-84